Lilly Gets Second EUA, For Baricitinib In COVID-19 Patients

 
• By Joseph Haas

Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.

Coronavirus globe
Lilly's second EUA for a COVID-19 therapy covers Olumiant in hospitalized patients

More from COVID-19

More from Scrip